Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281689 | 0.98 | EPHX1 (0.50) | EPHX1SMN1; SMN2SHBGALDH1A1KDM4E | |
| SCHEMBL28995693 | 0.96 | EPHX1 (0.42) | EPHX1SMN1; SMN2CA1CA2CPN1 | |
| SCHEMBL4188387 | 0.92 | CA1 (0.38) | EPHX1SMN1; SMN2CA1CA2CPN1 | |
| SCHEMBL1478217 | 0.89 | CA1 (0.46) | EPHX1CA1CA2METAP1DPP4 | |
| SCHEMBL1478219 | 0.89 | CA1 (0.46) | EPHX1CA1CA2METAP1DPP4 | |
| SCHEMBL931251 | 0.87 | EPHX1 (0.47) | EPHX1CA1CA2METAP1DPP4 | |
| SCHEMBL4537552 | 0.85 | LCK (0.42) | EPHX1ALDH1A1 | |
| SCHEMBL11010077 | 0.84 | EPHX1 (0.44) | EPHX1ALDH1A1 | |
| SCHEMBL27719303 | 0.84 | EPHX1 (0.44) | EPHX1ALDH1A1 | |
| SCHEMBL2752774 | 0.83 | EPHX1 (0.50) | EPHX1SHBGALDH1A1CPN1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101239975-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | claimed |
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | claimed |
| CN-1771246-A | Synthesis of 2-butyl-3- (2' - (1-trityl-1H-tetrazol-5-yl) biphenyl-4-yl) -1, 3-diazaspiro [4.4] non-en-4-one | TEVA PHARMA (IL) | 2006-05-10 | — | — | CN | claimed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | claimed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| CN-101239975-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | disclosed |
| CN-101239930-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | disclosed |
| CN-101239974-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | disclosed |
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | disclosed |
| US-7312340-B2 | Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-25 | — | — | US | disclosed |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | DOLITZKY BEN-ZION | 2006-06-15 | — | — | US | disclosed |
| CN-1771246-A | Synthesis of 2-butyl-3- (2' - (1-trityl-1H-tetrazol-5-yl) biphenyl-4-yl) -1, 3-diazaspiro [4.4] non-en-4-one | TEVA PHARMA (IL) | 2006-05-10 | — | — | CN | disclosed |
| US-7038060-B2 | Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-05-02 | — | — | US | disclosed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | disclosed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | AGTR1, AGTR2, TEK | EPHX1 1772/4885SMN1; SMN2 4121/4885SHBG 2616/4885 |
| US-20060128967-A1 | Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | AGTR1, TEK, AGTR2 | EPHX1 1578/4885SMN1; SMN2 3892/4885SHBG 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.